S Eswara Reddy rejoins as joint drug controller after Centre revokes suspension

After the Union government revoked his suspension on December 26, former Joint Drug Controller S Eswara Reddy has rejoined the apex drug regulatory body.

The Delhi High Court granted bail to both Reddy and Biocon’s associate vice-president Praveen Kumar.

According to the CBI, three people were arrested in June after they were allegedly bribed to waive off a clinical trial requirement for a diabetes drug developed by Biocon Biologicals. The company, a Biocon subsidiary, has denied the charges.

Reddy was arrested on June 21 for allegedly taking a bribe to waive off the phase-3 clinical trial of the Insulin Aspart injection of Biocon Biologics. On July 19, a CBI court in Delhi rejected his bail application and those of Biocon Biologics’ Associate Vice President L Praveen Kumar and three others.

Reddy alleged that the proceedings were “part of some larger conspiracy not to let him appear for the interview for the above post (DCGI) though despite (CBI) proceedings, no departmental enquiry has been instituted against him”.

He didn’t elaborate on the conspiracy or those who were part of it.

He also told the court that due to his “impeccable career and character”, he was appointed interim Drug Controller of India from February 2018 to August 2019 and was likely to be appointed as such.

Opposing the bail plea, the CBI said they caught Reddy while he was accepting Rs 4 lakh from Dinesh Dua, director at Synergy Network India Private Limited.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction